Time burden and healthcare costs associated with docetaxel in patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating an androgen receptor pathway inhibitor (ARPI) –based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results